 |
|
|
| |
Safety of Ledipasvir/Sofosbuvir with and without Ribavirin for the Treatment of Patients with Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION trials
|
| |
| |
Reported by Jules Levin
IAS 2015
The 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), 19-22 July 2015, Vancouver, Canada
N Bräu1, S Alqahtani2, N Afdhal3, S Zeuzem4, S Gordon5, A Mangia6, JC Yang7, J Wolf7, X Ding7, PS Pang7, MS Sulkowski2
1Mount Sinai School of Medicine, Division of Infectious Diseases and Liver Diseases, Astoria, New York, United States; 2Johns Hopkins Medical Center, Baltimore, Maryland, United States;3Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; 4Johann Wolfgang Goethe University, Frankfurt, Germany; 5Henry Ford Health System, Detroit, Michigan, United States; 6Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 7Gilead Sciences, Inc., Foster City, California, United States
|
| |
|
|
|
|
|
